

⇒ Eric Rosenthal reports

Ohio State Hosts Big Dance with Industry, Hoping for Successful Research Partnerships

By Eric T. Rosenthal

OLUMBUS, Ohio—National rankings rank high as a priority at Ohio State University. In early December here as the University's Medical Center was hosting its first Industry Collaboration Symposium, its football and basketball teams were both ranked number one in the nation.

Fred Sanfilippo, MD, PhD, the Medical Center's CEO, as well as Senior Vice President, and Executive Dean for Health Sciences, opened the conference by informing the audience of more than 300 about OSU's accelerating place in soveral US Nave & World Report

several *US News & World Report* medical rankings.

He said he wanted the Medical Center's rankings to be the subject of pride for both its football and basketball teams, noting that the basketball reference had also been used extensively during his days at Duke.

The conference was a key part of the Medical Center's strategic game plan, and mixed show-and-tell with the dating game in an effort to forge future partnerships with industry.

Dr. Sanfilippo told *OT* that the symposium was the brainchild of Henry Zheng, PhD, MBA, Director for Technology Commercialization and Partnerships at the Medical Center.

"The conference was another step in our pathway of providing experience and education to our faculty about the opportunities with each other here in research as part of our strategic plan and signature programs, as well as with a wide range of industry."

The medical center had spent a lot



Fred Sanfilippo, MD, PhD, CEO and Executive Dean for Health Services at OSU Medical Center, noted that the medical center had spent a lot of time on organizational culture and culture change during the last several years, and the symposium was a component of inculcating a spirit of collaborative approaches, innovation, and entrepreneurship.

of time on organizational culture and culture change during the last several years, Dr. Sanfilippo explained, and the symposium was a component of inculcating a spirit of collaborative approaches, innovation, and entrepreneurship.

"We'll have our athletic leadership come to our retreats involved in culture change to teach collaboration and teamwork, and you can't beat the athletic examples when it comes to team building," he said.

Another goal, though, he admitted, was to showcase OSU's recently

opened Biomedical Research Tower, which was built to foster interaction among the medical center's six signature programs in cancer, critical care, heart, imaging, neurosciences, and transplantation.

Interaction of Cancer & Transplantation

Dr. Sanfilippo said that the presentation of Michael Caligirui, MD, during the conference was a good example of interaction between two otherwise disparate disciplines—cancer and transplantation—since the goal of one was to stimulate immunity and the other was to suppress it.

Dr. Caligiuri, Director of the OSU Comprehensive Cancer Center and Deputy Director of the James Cancer Hospital and Solove Research Institute, discussed his laboratory's current research on the development of a vaccine against the Epstein-Barr virus (EBV), which can lead to B-cell lymphoma in some post-transplant patients.

He is looking at how manipulation of various parts of the immune system can possibly contain the lymphoma.

The conference was a big deal for Ohio State University, and mixed show-and-tell with the dating game in an effort to forge future partnerships with industry.

Eric T. Rosenthal is OT's Special Correspondent.



Other cancer center talks included:

- Carlo Croce, MD, on evolving research that links specific microRNA signatures to various types of cancer.
- Jeffrey Chalmers, PhD, on a prototype of a new cell-sorting technology that uses magnetized antibodies to tag and isolate cancer cells in peripheral
- Pravin Kaumaya, PhD, on novel peptide-based vaccines and immunotherapeutic approaches for breast cancer. At the conclusion of his talk, Dr. Kaumaya was not shy about incorporating a slide that said: "Need corporate partner to invest and accelerate development of Phase II \$3-4 million"—a request that was certainly targeted to the right audience. Dr. Kaumaya seemed to be representative of what symposium organizer Dr. Zheng considers a small core of OSU faculty who see the value of getting intellectual property into the market.

Educational Exposure to Industry

During a follow-up call, Dr. Zheng said that the conference was largely created to provide the mainstream faculty with an educational exposure to industry.

"When our faculty members attend conferences they usually only meet (continued on page 20)

Eye on Washington

against drug companies if they or a loved one become seriously ill or die as the result of a particular drug. And in just the last few days, the FDA has approved numerous waivers for panelists on its advisory boards who have financial conflicts of interest with drugs and devices they are reviewing.

continued from page 18

"The FDA is broken and is need of significant, comprehensive reform; not just to the laws that govern the agency, but also to the culture that pervades it. As a member of the House Appropriations Subcommittee that has jurisdiction over the FDA's budget, my colleagues and I will closely be following Dr. von Eschenbach's work as FDA Commissioner and will fully exercise

our panel's oversight authority of the agency."

Study: Growth in Health Care Spending Much Faster than Growth in Ages

The growth in health care spending stayed high in 2005 as costs for Americans with private insurance rose 7.4%, the same rate as the previous two years, according to a study by the Center for Studying Health System Change in Washington, DC.

Health spending growth outpaced overall economic growth, despite a 5.4% increase in the overall US economy. After peaking at 10.4% in 2001, health care spending slowed to 7.8% in 2003, followed by 7.5% in 2004. Spending data for the first quarter of 2006

suggest continued stability, albeit at a relatively high rate of growth: 7.7%.

"Health care spending continues to grow at a much faster rate than workers' income, making health insurance less affordable to more and more people, especially low-to-moderate wage earners and their employers," said the Center's President and the first author of the report, Paul B. Ginsburg, PhD. "We're already seeing evidence of the growing health insurance affordability problem as more Americans become uninsured."

The slowdown in employer-sponsored health insurance continued in 2006 as the cost of premiums increased significantly. For the fifth year in a row, employers increased patient cost-sharing in 2006 through higher deductibles, copayments, and coinsurance. Without this benefit "buy down," the premium

trend would have been even higher.

"Premium increases cannot be lower than underlying cost trends without further reducing benefits," Dr. Ginsburg said. "So major relief from the financial burden of rapidly rising premiums does not appear to be on the horizon."

The study found that trends in three categories of health services contribute to the problem:

- Prescription drug spending increased at a slower pace, due to slower growth in utilization rather than slowing of drug price increases.
- Spending on in-patient and outpatient hospital services increased. This included freestanding facilities such as surgery and imaging centers.
- Spending on physician care, home health care, and ambulance services increased



Collaboration

continued from page 19

with other scientists, and don't experience the trade-show side. Slightly more than half the attendees were from industry, and the rest were mostly researchers from OSU and a few other universities," he said, adding that a major objective was to promote an entrepreneurial culture.

Dr. Zheng said that the value of intellectual property was more of a policy issue because most universities don't really encourage or include that or invention in tenure or promotion decisions.

He said universities like Emory, MIT, and Stanford have best practices of encouraging faculty to move invention and innovation to the market, and said he agreed with the University of Michigan's point of view that institutions have a public service mission to translate tangible assets for economic development that benefits society.

"Many people here don't really understand the point that there's a certain social value involved with technology transfer. And some universities are now including technology as part of

Henry Zheng, PhD, MBA, **OSU Medical Center's Director of Technology Commercialization &** Partnerships, noted that universities like Emory, MIT, and Stanford have best practices of encouraging faculty to move invention and innovation to the market. He agreed with the University of Michigan's point of view that institutions have a public service mission to translate tangible assets for economic development that benefits society, he said. "Many people here don't really understand the point that there's a certain social value involved with technology transfer. And some universities are now including technology as part of tenure decisions."

tenure decisions."

He said the Industry Collaboration Symposium was not a typical meeting and because of the expenses involved, the university had asked industry to help support it, making it a budgetneutral event.

"During the last 10 to 15 years," Dr. Zheng noted, "Ohio State has only had one invention—the feline leukemia vaccine—that has brought in substantial income—about \$2 million a year. But when the patent expired, we stopped receiving that money and our annual licensing revenue dropped to only

about \$600,000, which was a huge blow.

"We have to develop a line of technology that we can keep pushing to the market."

Dr. Zheng said that invited companies were chosen either because they had preexisting relationships with Ohio State or were viewed as potential part-

The Johnson & Johnson Example

One potential partner was Johnson & Johnson's Corporate Office of Science

and Technology (COSAT), which was created in 1978 to foster Johnson & Johnson's long-standing focus on innovation and entrepreneurship, according to its Web site.

Robert Zivin, PhD, Corporate Director for COSAT, asked to speak on a panel dealing with industry research and collaboration, said that academic centers ask questions that industry can't afford to ask, and noted that Johnson & Johnson's COSAT was targeting top universities to fund early research of relevance to health care without asking for rights.

In metastatic breast cancer*> The next generation



*ABRAXANE® for Injectable Suspension is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

of possibilities

ABRAXANE, the first and only albumin-bound taxane, significantly all randomized patients


- patients treated with AER AXANE was nearly double. that of patients treated with solvent-based paclitaxel
 - 21.5% vs 11.1% (P=.003) for all study patients!
 - 15.5% vs 8.4% (PHNS) for study patients who failed. combination chemotherapy or relapsed within 6 months of adjuvant chemotherapy

To learn more about ABRAXANE, visit our Website at www.abraxane.com

Embrace the next generation

Abraxane' for Injectable Suspension

(pacilitate) pretein bound particles for injectable suspension) talbania board









During a subsequent telephone interview, Dr. Zivin said that J & J operated more than 200 companies worldwide with more than 10,000 scientists and that, once acquired, companies maintained their independent identities.

He said that J & J was also guided by its corporate credo that stressed fulfilling the company's responsibilities to its customers, employees, the community, and its stockholders.

"I wasn't very familiar with the research programs at Ohio State when I went there, but I was happy to come,

OSU's recently opened Biomedical Research Tower was built to foster interaction among the medical center's six signature programs in cancer, critical care, heart, imaging, neurosciences, and transplantation.

and once I was there I wondered why I wasn't there sooner," he said.

Dr. Zivin explained that a number of the university's research programs had recently broken into the top 10, and

it was as if OSU had broken through the sound barrier, commanding attention for possible collaborative efforts.

"We believe the future of pharmaceuticals is in partnerships where company researchers and academic researchers act as collaborators more than as sellers and customers. We don't know what science will lead to in breakthroughs, and because no company can afford to secure every piece of intellectual property, our security is in working toward relationships with academic researchers."

Dr. Zivin said COSAT supports a broader view based on these relationships and on the science, adding that the appropriate time for formal contracts would be dictated by develop-(continued on page 22)

WARNING: ABRAXANE for injectable Suspension (paditanel protein bound partides for injectable suspension) should be administered under the supervision of a physician experienced in the use of cancer demotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.

ABRAXANE therapy should not be administered to patients with metastatic breast cancer who have baseline neutrophil counts of less than 1,500 cels/mm². In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving ABRAXANE.

Note: An albumin form of paditanel may substantially affect a drug's functional properties relative to those of drug in solution. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS.

Important Safety Information

In the randomized metastatic breast camer study, the most important advase events induded neutropenia (all asses 80%; severe 9%), anemia (all 33%; severe 1%), infections (24%), sessory neuropathy (any symptoms 71%; severe 10%), mausea (any 30%; severe 3%), vaniting (any 18%; severe 4%), diambea (any 26%; severe <1%), myalgia/artimalgia (any 44%; severe 8%), and mausicis (any 7%; severe <1%). Other advase reactions induded astheria (any 47%; severe 8%), ocular /visual disturbances (any 18%; severe 1%), fluid retention (any 10%; severe 0%), alopecia (90%), helpatic dysfunction (elevations in lish abit 7%, alkaline phosphatase 36%, AST ISGOTI 39%), and rend dysfunction (any 11%; severe 1%). Thrombodytopenia (any 2%; severe <1%), hypesenitivity reactions (any 4%; severe 0%), and divascular reactions (severe 3%), and injection site reactions (1%) were ancommon.

Warnings, Precautions, and Contraindications

The use of ABRANANE has not been studied in patients with hepatic coveral disferention. In the randomized controlled this pathets were excluded for baseline seven bilibulah > 1.5 mg/dL corbaseline seven contribute > 2 mg/dL

ABRAMANE can cause fetal hazen when administered to a prognant woman. Women of childbearing potential should be advised to avoid becoming prognant while receiving treatment with ABRAMANE.

Wonshould be advised to not father a child while receiving treatment with ABRANAME.

ABRANANE contains a baumin (numan), a derivative of human blood.

Caution should be associated when administrating ABRAMAPIE concentrantly with lenous substrates or inhibitors of CYP2C8 and CYP3A4.

t is recurrenced at that prepare peripheral blood cell courts be performed on all patients receiving ABRAMANE Patients should not be retreated with subsequent cycles of ABRAMANE until neutrophils recover to a level > 1,500 cells/inm² and platelets recover to a level > 100,000 cells/inm².

In the case of severe mutopania (<500 cells/inut for 7 days or more) during a colose of ABRANANE through, a dose reduction for subsequent coloses is recommended.

Sourcey more opathy occurs frequently with ABRANAME. The occurrence of goads 1 or 2 security new opathy does not generally require does modification. If goads 3 security neuropathy develops, treatment should be withheld with resolution of goads 1 or 2 followed by a does reduction for all subsequent courses of ABRANAME.

t is recovered at that musical be discontinued when receiving ABRAKANE therapy.

Sovon cardiovascular overts possibly related to single-agent ABRAVANE occurred in approximately 2% of patients in the randomized trial. These events included chart pain, cardiac areat, supraventricular to descardia, edema, thrombosis, publicancy thromboombolism, publicancy embodism, and hypotension.

Please see Warnings, Precautions, and Contraindications in the Prescribing Information on the following page.

R×Ddy



Collaboration

continued from page 21

ment of the science.

He likened his office to sort of a "scientific social director," or a clearinghouse or introductory matchmaker, that fostered communication among the thousands of decentralized J & J scientists as well as with basic researchers at academic centers.

And he said he was looking forward to future discussions with university scientists.

Genentech & Innovation

Another panelist during the research and collaboration session, Joseph S. McCracken, DVM, Genentech's Vice President of Business Development, said, "Real innovation is the key to success for all of us in the health care industry."

Noting the public's current poor perception of the pharmaceutical industry, he was critical about the motivations of some pharmaceutical companies, stating there were three types of innovation: exponential, incremental,

and excremental.

He mentioned Clarinex and Nexium as examples of "taking old drugs and spending \$250 million in direct-toconsumer advertising to convince the public it's the best drug without data."

He said cooperative efforts should follow the science and not the markets, explaining that it was commercially driven market plans that often got pharmaceutical companies into trouble.

In an interview Dr. McCracken said his purpose for attending the symposium was to tell Genentech's story and explain some areas of biology of

Joseph S. McCracken, DVM, Genentech's VP of **Business Development,** said that real innovation is the key to success for all in the health care industry. Noting the public's current poor perception of the pharmaceutical industry, he was critical about the motivations of some pharmaceutical companies, stating there were three types of innovation: exponential, incremental, and excremental.

Abraxane^{*} for Injectable Suspension. إطمارية فأعارأ أبا بزاران استا شام إسارة

ACC ACCIDENT AND ACCIDENT ACCI

HINDON DE COMMENTATION DE COMM

PACE BIOS.

Here we want appear is a finished to reduce this first dependent and a distribution in the finished being distribution for the finished between the finished between

ageta.

**Transport Continues of the AdV suprement Continues o

nam de er en englief hell). De er en er elegel en de erleicheld deller L. pepual er en mehr 600 fill. I M. dy mehr delig progresse de lie yelle framer y geschielte werke, ik des, fir yellel de all er yeller i De yelle hell de bedekt de delige de geschielte de alle en de reit er kap oppaal elde werk ig de hell el 600 fill.

Such Afficials
The chair had been been added for each type based 48, 46 Castle for FOR AFFICE
Could provide provide provide a public of a suffering been as to the first a sufficient as the could be a sufficient as the c

Note the ground of the second of the second

Angeleg – Berlapik Madifesperagisky api Ger (2000 maly)

OFF Contract Services

Black Black, Adding a third becoming to the Silv Apitheres in which below to the deblack Black Associating and with recorded blacks, and the Silv Apitheres in which below to the Apitheres in the Silv Apitheres in the

Amerikalı direc Türk deliy adırılmığı seri ildi. HOCM Milleyallı biyyıllığı kileyi direk ildi. Filmili direce ildi. Filmili de

 - many particles in the contracted design of the contract design of the contract ARABE BOLATING

This is the grown speed deeps for all Treates and Beauty and All section flower in the first Combination is that year on the speed Works is also deter			
	h=	Promodel Publish	
	ASTACAMI TOTAL	Resilies Helper Ser Digital > Deficial	
Com Harmer			
16 ab apos 6/ a 23 a 64. a 63 a 64.	7	3	
The chapter est. a SE : Brj. a SE : Brj.	3	3	
Amerika n Hapita n Bapita	7	3	
الشارات	7	1	
Parkets (Instruments)	1		
C leading	3	1	

	Parada (N. Sada	
	AETAGUE	No Shoul I specified
	Market by	CRAPA .
	le Partie	1000
I personal felt plan alle a c		
Au .	-	-
1007		,
Cod home sho		
Phillip Charm'		
Enalpsonito	•1	
		-
Barra Cuel Income to Breats'	- i	-
Amerika Amerika		
All publish	-	-
Pulled and the colling	-	-
Emarko.		<u> </u>
<u> </u>	-	- :
- Property		-
Complete spelly.		
Ang Byraphana	71	-
Lengtherine		
Hydrogle (Addressed) a		
Ang B prophoson		•
lara e l'orgin del	,	•
Andre de		
Artodes		
I are a I popie car	3	3
Place Code Service		
Artodes	_	1
Large Louisse'		
(bosse)		
Agranusiana	-	21
Improvincia	- 7	- #
President		
Ang agraphica	-	-
Appendix		- : -
lame I native	-	
Planting	-	•
Ang Byrgham		
Barrier Byraphican'	•1	-
Art Indian	-	2
Date of Prophers	•1	

144		
Publish Albiha ad Cambril		
C Blookin B beralle on	,	,
Alle the Permit Arm Bloods on		21
	,	
bpd to the Courts		- 1
Constant on the sale		

the time to the 100 and All processing as any entry construction.

The shape ship for and large in all constraints in the shape of the constraints of an entry find the same of the same shall be and shall be an entry find the shall be been done to the same shall be an entry find the price of the shall be an entry find the price of the shall be an entry find the SM (100 pt).

In the main shall be the shall be an entry find the shall be a corn against the SM (100 pt) the shall be an entry find the shall b

Confloration.

By Arthody, adding the Privated highly present to the Lipschick to the restrict of electric to the Lipschick to the Confloration of the Red product of the Lipschick to the Confloration of the Red product of the Confloration of the Red product of the Lipschick to the Red of the Red to the Red

Consistent of the control of the con

Autophopy parties of the best file and and this period of delph haping All approach to the best file and the best file a

e g Brita A. E. a met fin erlier her dessite a breieri A. de 1920 B. E. er erde sched ist (, 19, 27 k), M. Lateria B. a. Li Marke, Brita y La (Libra y Later) 1970 M. E. ya ya ribely alateki 27 ki eris B. a. Cours aya her brita 1984 I. julia bersite AL 1982 B. Brita 1984 (1) dessit 1 bersit A. ya de A. La Branch and 1884.

Commy significant to commit and large in many last prility in the first in the first committee in the principle of the many that the principle of the many that the principle of the first in the first

des d' le red 11 Maignith agretant un libertant a, Minara in dinadiantes, des estation, es des dels ceremonity en là biles.

of table (M. Caralla, September 1994). A September 1994 of the contract of the first state of the September 1994 of the contract of the September 1994 of the contract of the September 1994 of the Se

del pull has combiblished po disco. De para 1915 descriptions disc_o il la subhidde de abouty consider il de labora, elle de que il the descriptions de about de la companyone de la subhidde de abouty consider il de la companyon il territorio de la

this (Alberts).

It is also being the second of the second

effectivity companies to the College State from exerting the companies that the college should be suffered to the companies that the college should be suffered to the college s

FARTHER FOR

The risk of the best of CARRE continues. The plane college is may be for all continues and marked in the control of the continues of the college of the college is the college of the colleg

Ay his could by the restable to the first of the region of the COMM.

Any provides and Anhib Rabella Area of the region of the r



L. dary he by you will be red. of the place of soil of 400 to the Children of the State of the S

Chick the round this for the relative special requests required to the plant by the plant of the

Be. (WO-DEM : Hitspile stage versich bie Bergeschapelle seine.

North Could be appeal and to a 1997 to 1998 to 1998, Color to the explicit purpose product beautiful to the color of the c

ben hijdigat.

di salla, sari dispusari.
Terrelan hiji yang di digunahir sala sari dapi di sali be sa bibed. Newelpabilika sa bib salah bang pelasilika sa di digunahir salah salah di salah benyar pelasiliki. Terrela sarah persanahir di di salah persahan sarah sasah di bibe persahan sarah sarah di bibe pelasi sarah sarah sarah salah bang pelasilan sarah sarah sarah salah salah

TO HERE CELL

Library Laurch in the Strike in Laurch of Construct delices; in this buyer shallon in Laurch Cells (Director)

by the Department of Promoters, for the research SET delicy (Mary, A. Links, L.) (Const.)

Library Construction of Construction (Mary Cells of Construction)

Library Construction (Mary Cells of Construction)

Library Construction (Mary Cells of Construction)

Library Construction (Mary Cells of Cells

MPG. 7. Bit had Mindy County for an Calif in Experiment on convention to the selfing Calif is designed, the distinct for a Link C Arting May, On Imma, Bit and Palay County in Law Cylindric Experiment is a rather of hers Lash C. Arbing, N.N., Callesse, B. Bur J. May C. Lash Arbina, L. Quickell, Exposer I have shared Or Specific among and difficult for J. Arbina. Of the appear of the resp. 14 the 3, the substitute Coll. S. Chile Proceedings and Specific for the collection of the meanwhile substitute in the Specific following in the depths (Arbina) of the Specific following and the process of Day of these Start I had 26 if the Specific following in the Arbina Collection discovering a PDO (pp. 1994) and COL. Children Arbina (1994) and the Specific following in the Spe



ing right of Self allows H7 descriptions of A believes Planta service I U. all Opts Construction ли опортион и и

AstraZeneca 🕏

interest to Genentech "to maybe flush someone out of the corners of the laboratory who might say, 'Oh, I didn't know you were interested in that and I happen to be working on this or something else, and I think it may be an answer to one of your problems.""

He said he believed exponential innovation could be achieved through partnerships with academic institu-

Speaking directly to academic institutions, he said his advice was to seek out companies that want to change medical practice, identify areas of biology that both the institution and the company believe are important in serious diseases, pursue translational research to test hypotheses, and find efficient ways to work with companies and investors.

And finally Dr. McCracken's thoughts for venture investors: "It's not that the situation today is so bad...but that yesterday was so good."

"Take a long-term view," he said, "and believe in the value of innova-

During a post-conference call, Dr. Sanfilippo characterized the symposium as a "roaring success from all measures.

"I think we'll probably do it again, but I'd also like to do a debriefing, sort of a post-mortem," said the pathologist. "But certainly from reactions at the meeting, it looks pretty promising."

And time will tell if the event will lead to meaningful collaborations leading to potential advances in biomedicine benefiting the public.